Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
50°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BioNTech SE
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
April 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
April 07, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Planned Retirement of Sean Marett
March 07, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
March 06, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
January 31, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
January 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
December 21, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
December 18, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Inaugurate First African Site on December 18, 2023
December 12, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
November 06, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
October 23, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
October 23, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
October 19, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
October 16, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
October 16, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
September 28, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
September 18, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
August 30, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
August 14, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
August 07, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Completes Acquisition of InstaDeep
July 31, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
July 24, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
June 29, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.